Company profile for Axon Neuroscience

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Axon Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration. Ground-breaking discoveries in Alzheimer’s disease research made by AXON Neuroscience enabled the company to create a therapeutic platform of global importance. The target products of strategic importance in this platform are revolutionary therapeutic candidate v...
Axon Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration. Ground-breaking discoveries in Alzheimer’s disease research made by AXON Neuroscience enabled the company to create a therapeutic platform of global importance. The target products of strategic importance in this platform are revolutionary therapeutic candidate vaccines for treatment of Alzheimer's disease and Frontotemporal lobar degeneration.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Cyprus
Address
Address
Arch. Makariou & Kalogreon 4 Nicolaides Sea View City Block C, 5th floor Offic...
Telephone
Telephone
+357 2425 2636
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accesswire.com/657035/AXON-Neuroscience-to-Present-New-Results-from-Phase-II-Clinical-Study-at-2021-Alzheimers-Association-International-Conference

ACCESSWIRE
27 Jul 2021

https://www.accesswire.com/657035/AXON-Neuroscience-to-Present-New-Results-from-Phase-II-Clinical-Study-at-2021-Alzheimers-Association-International-Conference

ACCESSWIRE
27 Jul 2021

https://www.prnewswire.com/news-releases/nature-aging-publishes-phase-ii-results-for-aadvac1-a-first-in-man-alzheimers-tau-vaccine-developed-by-axon-neuroscience-301311724.html

PRNEWSWIRE
16 Jun 2021

https://www.prnewswire.com/news-releases/nature-aging-publishes-phase-ii-results-for-aadvac1-a-first-in-man-alzheimers-tau-vaccine-developed-by-axon-neuroscience-301311724.html

PRNEWSWIRE
15 Jun 2021

https://www.prnewswire.com/news-releases/nature-aging-publishes-phase-ii-results-for-aadvac1-a-first-in-man-alzheimers-tau-vaccine-developed-by-axon-neuroscience-301311724.html

PRNEWSWIRE
14 Jun 2021

https://www.prnewswire.com/news-releases/axon-neuroscience-to-launch-worlds-first-crowdfunded-vaccine-against-covid-19-301133925.html

PRNEWSWIRE
18 Sep 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty